Novigra

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Novigra

Property Description
Active ingredient Sildenafil citrate
Form Tablet (Oral)
Pharmacological class Phosphodiesterase-5 (PDE5) inhibitor
General Purpose Promotes vasodilation and increased blood flow
Origin Synthetic compound

Novigra is a prescription-only medicinal product, recognized by its branding and specific formulation containing the active compound, sildenafil, chemically prepared as sildenafil citrate. The active ingredient sildenafil is classified as a Phosphodiesterase-5 (PDE5) inhibitor. This pharmacological classification defines the drug’s core function within the body. The compound is synthetic in origin, which ensures a high-purity, consistent molecular structure for its targeted biological effect. The classification as a PDE5 inhibitor establishes its mechanism: it functions by the selective inhibition of the PDE5 enzyme, a characteristic that differentiates it from general, non-selective vascular dilators. This action is clinically recognized for its ability to mediate vascular responses in target tissues.


Composition, Form, and General Purpose

Novigra is a single-ingredient product administered through the oral route, typically in a film-coated tablet dosage form. This specific formulation is distinguished by its primary application in scenarios requiring support for peripheral circulation, such as promoting and sustaining enhanced blood flow in localized vascular beds. The fundamental purpose of this formulation is to manage the body's vascular response by promoting vasodilation, or the widening of blood vessels, in specific target tissues. The sildenafil compound achieves this by temporarily preventing the breakdown of a key natural signal (cGMP) that instructs the smooth muscle in the vessel walls to relax. The resulting localized increase in blood flow is the fundamental physiological outcome and the basis for the drug's intended general benefit.

Regulatory References

  1. Sildenafil: MedlinePlus Drug Information
  2. MedlinePlus

What side effects are possible with Novigra?

Novigra's (sildenafil) official safety profile is structured by regulatory authorities to classify potential adverse reactions based on their frequency and the body system affected.

Frequency-Classified Adverse Reactions

The most frequently documented reactions are classified based on their incidence in clinical trials. Headache is the only reaction classified as Very Common, meaning it occurs in more than 1 out of 10 users, according to regulatory data. Reactions classified as Common (ge 1/100 to <1/10 users) include flushing, dyspepsia (indigestion), dizziness, nasal congestion, and various visual disturbances (e.g., blurred vision or color tinge).

System-Organ-Class Safety

Adverse effects are also categorized by the physiological system they affect. Common effects are mapped to Vascular Disorders (flushing), Nervous System Disorders (headache, dizziness), and Gastrointestinal Disorders (dyspepsia). The label also notes effects within the Ocular and Musculoskeletal systems.

Serious Adverse Reactions and Restrictions

The prescribing information highlights several rare, but serious adverse reactions reported in post-marketing use, including reports of Non-arteritic Anterior Ischaemic Optic Neuropathy (NAION), sudden hearing loss, and Priapism (an erection lasting over four hours). Formal safety constraints are defined by Contraindications. The use of Novigra is strictly contraindicated with any form of nitrate or nitric oxide donor due to the potential for severe hypotension. Use is also restricted in individuals with severe cardiovascular events (e.g., recent stroke or myocardial infarction) and specific existing ocular conditions, such as a history of NAION or hereditary retinal disorders.

Overdose and Emergency Response

The official regulatory documents define the Novigra overdose profile by specifying the documented clinical manifestations and the required emergency actions. Overdose exposure typically results in the exaggeration of known adverse effects, which are reported to increase in incidence and severity.

Property Official Regulatory Statement
Documented Overdose Presentations Clinical manifestations include hypotension and syncope following high systemic exposure.
Physiological Systems Affected Primary systems include the Cardiovascular system and Ocular/Auditory systems (sudden sensory loss).
Population-specific overdose notes Patients with severe renal impairment or hepatic impairment may experience increased systemic exposure, raising the risk of dose-related manifestations.

Emergency Actions and Immediate Help

Property Label-Derived Phrasing
When immediate medical help is required Seek immediate medical assistance for any erection persisting longer than 4 hours; seek medical care immediately for sudden decrease or loss of vision or hearing.
Supportive Management Measures Management is based on the adoption of standard symptomatic and supportive measures. No specific antidote is known for this compound.
Overdose-Context Constraints Renal dialysis is not expected to accelerate clearance due to the drug’s high plasma protein binding.

Official Overdose Statements

Overdose exposure mandates immediate action to prevent severe outcomes. The documented risk of a prolonged erection (priapism) requires that help be sought promptly to prevent penile tissue damage. The documented risks of acute sudden loss of vision or hearing also require immediate medical attention as stated in the prescribing information. This approach ensures clinical management is guided strictly by regulatory requirements.

Therapeutic Uses of Novigra

What Novigra Treats: Main Uses and Benefits

Novigra is commonly used to help with certain distressing symptoms linked to conditions where functional stability becomes affected. It is applied across domains where short-term symptomatic assistance is appropriate and is relevant when supportive relief is needed for symptom categories such as heightened physiological activity, systemic imbalance, and noticeable functional strain.


Easing Episodes of Heightened Discomfort

This medicine is often used during phases when symptoms become more noticeable, particularly those symptoms related to systemic imbalance. Novigra provides support that helps ease the overall symptom burden and contributes to improved comfort during periods of heightened symptoms. The medication is applied to address symptom clusters that may become intense or disruptive, such as during acute or episodic changes.

“Novigra may be part of symptomatic management applied in scenarios where additional management of discomfort is required.”

Support for Stability and Function

Novigra is useful in scenarios where symptoms escalate temporarily, and is applicable in conditions involving episodic or fluctuating manifestations. It supports general well-being during symptomatic phases and assists with maintaining functional stability by helping patients cope more steadily with symptom fluctuations.

Quick Fact: Relevant for Symptoms of Heightened Physiological Activity

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Official Eligibility and Use Restrictions

Novigra is subject to several official eligibility constraints as outlined in authoritative regulatory labeling, defining the patient groups who may or must not use the medicine.

Contraindicated Populations (Must Not Use) Eligibility-Related Restrictions
Patients with a known history of serious hypersensitivity reaction to Novigra or any of its inactive components. Endocrine Tumors: Not recommended for patients with a personal or family history of Medullary Thyroid Carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Type 1 Diabetes Mellitus (T1DM): Explicitly stated in the Limitations of Use that the product is not indicated for T1DM.
Age: Use in pediatric patients (under 18 years of age) has not been established.
Gastrointestinal Disease: Not recommended for patients with severe gastrointestinal disease due to lack of specific study data.
Pregnancy/Lactation: Use during pregnancy and breastfeeding is generally not recommended unless the benefit is determined to outweigh the potential risks based on regulatory risk assessments.

Eligibility to use Novigra is therefore formally excluded for patients with known hypersensitivity reactions. Furthermore, regulatory documents place significant constraints on use by restricting the medicine in populations with a history of specific endocrine tumors and defining it as non-indicated for Type 1 Diabetes. This official documentation strictly regulates the eligible population.

What should I know about interactions with other medicines?

Novigra Interactions with other medicines and products

This section details interaction patterns documented in official government regulatory sources.

Contraindicated Combinations

Novigra is strictly contraindicated with all medicinal products containing organic nitrates or nitric oxide donors due to the serious risk of severe potentiation of hypotensive effects. Co-administration with the guanylate cyclase stimulator Riociguat is also strictly prohibited. The safety of combining Novigra with any other PDE5 inhibitor is not established and should be avoided.


Interactions Affecting Exposure (Pharmacokinetic)

Novigra is primarily metabolized by the CYP3A4 and CYP2C9 enzymes. Co-administration with strong CYP3A4 inhibitors reduces the drug’s clearance, leading to significantly increased plasma concentrations. For instance, the highly potent inhibitor Ritonavir causes an 11-fold increase in systemic exposure (AUC), necessitating a specific maximum dose restriction. Conversely, CYP3A4 inducers such as Rifampin and Bosentan are expected to decrease Novigra plasma levels. Reduced clearance resulting in higher systemic exposure is also documented in patients with severe hepatic impairment.


Additive Effects (Pharmacodynamic)

The drug has vasodilatory properties, and co-administration with alpha-blockers or general antihypertensive agents may result in additive blood pressure lowering effects. Caution is required due to the potential for symptomatic hypotension. Furthermore, official documentation notes that Grapefruit Juice may cause a modest increase in plasma concentrations, and the herbal product St. John's Wort may reduce concentrations via enzyme induction.

Mechanism of Action

The action of Novigra is defined by its molecular interaction with the enzyme that regulates the cyclic Guanosine Monophosphate (cGMP) signaling pathway in blood vessel cells.

Enzyme Inhibition and the cGMP Signaling Cascade

Novigra's core mechanism is the selective competitive inhibition of the Phosphodiesterase type 5 (PDE5) enzyme, which is abundant in vascular smooth muscle. This inhibition prevents the rapid breakdown of the key messenger molecule, cyclic Guanosine Monophosphate (cGMP). By preserving cGMP, the molecule acts to maintain the signaling state initiated by Nitric Oxide (NO).


Targeted Modulation of Vascular Smooth Muscle Tone

The accumulation of cGMP activates a sequence of events within the arterial smooth muscle cells that ultimately leads to a significant decrease in intracellular calcium levels. This drop in calcium causes the vascular smooth muscle to relax, a physiological change known as vasodilation. The resulting physiological consequence of this localized widening of blood vessels is a mechanical effect that supports increased blood volume in the targeted tissue.


Conditional Mechanism and Specificity

The mechanism is dependent on the prior, localized release of Nitric Oxide (NO); the drug only enhances the natural signal and does not initiate the process itself. This conditional nature limits the drug's maximal effect to specific areas where the physiological NO signal is active. The molecule exhibits a high affinity for PDE5, though its selectivity is not absolute, involving lower-affinity interaction with a related enzyme, PDE6, which is localized in the retina.

Dosage and Administration Information

How Novigra is Used: Official Administration Guidelines

This section details the established principles for administering Novigra (sildenafil citrate) concerning its use in adult men.


Approved Route, Form, and Frequency

Novigra is administered via the oral route as a film-coated tablet and is available in official strengths of 25 mg, 50 mg, and 100 mg. The medication is intended for as-needed use, and the maximum recommended dosing frequency is limited to once per day.


Standard Dosing and Timing

The usual starting dose for Novigra is 50 mg. This dose should be taken approximately one hour before activity, though it may be taken anywhere from 30 minutes to 4 hours in advance. The dose may be adjusted based on individual response and tolerability, ranging from a minimum of 25 mg up to a maximum recommended dose of 100 mg.


Administration Context and Adjustments

Novigra may be taken with or without food. However, administration with a high-fat meal may delay the onset of effect. A critical procedural condition is that sexual stimulation is required for the medicine to be effective.

Dose consideration is necessary for specific populations:

  • Older Adults (65 years and older): A lower 25 mg starting dose should be considered.
  • Impaired Organ Function: A 25 mg starting dose should be considered for patients with severe renal or hepatic impairment.
  • Drug-Specific Interactions: A maximum dose of 25 mg within 48 hours is specified when co-administered with Ritonavir.

Recent Clinical Evidence

Novigra, which contains sildenafil citrate, has been studied primarily in two major clinical contexts. The evidence base relies heavily on large, formal Randomized, Double-Blind, Placebo-Controlled Trials (RCTs), where measured outcomes in one group are compared to an inactive substance (placebo). This research design is used to explore patterns related to measured outcomes in the observed populations.


Evidence for use in Supporting Functional Stability

The research for Novigra's application in situations affecting functional stability (Erectile Dysfunction) involved numerous RCTs. These studies were applied in research contexts involving fluctuating symptoms, and researchers monitored short-term changes in patient-reported outcomes using validated questionnaires, such as the IIEF score. Findings describe patterns observed in the studies where questionnaire scores and activity tracking show patterns related to outcomes measured in the study compared to the placebo groups. Data for certain groups remain insufficient, particularly those with specific forms of severe underlying conditions.


Evidence for use in Improving Exercise Capacity

Novigra was also studied for its use in Pulmonary Arterial Hypertension (PAH). Research explored conditions marked by systemic imbalance linked to physiological strain. The key research measures included the objective Six-Minute Walk Distance (6MWD) and tracking the time to a clinical worsening event used to track outcomes over time. Evidence quality varies across studies, and limited data are available for patients with severe liver or kidney impairment. Regulatory cautions exist concerning certain dosing regimens in the pediatric population.


Long-Term Studies and Follow-up Durations

Evidence is available from both short-term RCTs (typically 12 to 24 weeks) and long-term open-label extension studies that tracked patients for up to three years. These longer studies contribute to the broader evidence landscape by helping to contextualize patient-reported experience over extended follow-up.


What is Still Uncertain About Novigra Research

There is limited information for long-term outcomes that fully characterize the status of patients many years after starting treatment. Comparative evidence is lacking in some areas, meaning direct, head-to-head comparisons against other medicines are not always available for every outcome studied. Research is ongoing to continue expanding understanding.

Frequently Asked Questions (FAQ)

Common questions about Novigra (FAQ)


Q: How quickly does Novigra generally start working?

A: Official patient guidance indicates that the effects of Novigra typically begin between 30 and 60 minutes after a dose is taken. However, regulatory documents note that if the medicine is taken with a high-fat meal, the onset of the effect may be delayed.


Q: Can Novigra cause me to feel tired or drowsy?

A: Official safety reports list fatigue (tiredness) as an uncommon adverse reaction associated with the use of the medicine. While the most common reactions are headache and flushing, this information from official product information helps inform users of less frequent general body effects that have been reported.


Q: What is the difference between Novigra and a generic version of the drug?

A: Regulatory authorities approve a generic version only after studies demonstrate it is bioequivalent to the branded product, Novigra. This means the generic delivers the same amount of the active ingredient, sildenafil, into the bloodstream and is considered to have the same safety and effectiveness profile.


Q: Can older adults use Novigra?

A: Regulatory documents indicate that older adults (those 65 years of age and over) may use Novigra. Because the clearance of the drug may be reduced in this population, regulatory guidance states that a lower starting dose should be considered by prescribers.


Q: Is Novigra generally considered suitable for people with kidney problems?

A: Novigra has been studied for use in people with kidney problems. Official prescribing information states that for patients with severe renal (kidney) impairment, a lower starting dose should be considered due to potentially increased exposure to the drug in the body.


Q: Do any official sources mention liver issues with Novigra?

A: Yes, official regulatory documents note that for individuals with severe hepatic (liver) impairment, the need for a lower starting dose is noted. This is because the clearance of the medicine from the body may be reduced, leading to increased exposure.


Q: Can Novigra be used by children?

A: Novigra, for its primary use (ED), is not indicated for individuals under the age of 18. However, the active ingredient, sildenafil, is approved by regulatory bodies under a different brand name and dosing regimen for the treatment of Pulmonary Arterial Hypertension (PAH), a different condition.


Q: What official information is available about Novigra's use during pregnancy?

A: Novigra for ED is not indicated for use in women. For the compound's other uses, official risk summaries note that human data are currently insufficient to fully inform a drug-related risk in pregnant women. However, animal studies conducted have not shown evidence of harm to the fetus.


Q: Does Novigra interact with alcohol?

A: Regulatory information notes that Novigra has vasodilatory (blood vessel widening) properties. The use of alcohol may result in an additive blood pressure lowering effect, which could potentially lead to symptoms such as dizziness or lightheadedness.


Q: Are there specific times of day Novigra should or shouldn't be taken?

A: The medication for this use is intended to be taken on an as-needed basis, approximately one hour before activity. Official guidance states that Novigra must not be taken more than once per day, but otherwise does not specify a mandatory time of day for administration.


Q: Is Novigra safe for use if I have heart disease?

A: Regulatory documents strictly prohibit Novigra's use with any medication containing nitrates. They also list several specific heart-related conditions, such as a recent heart attack, unstable angina, or specific types of heart failure, that are defined as reasons to avoid use according to regulatory documents.


Q: Is there a difference in how Novigra affects men versus women?

A: The official indication for Novigra (for ED) is for adult men. Official regulatory documents formally state that the medicine is not indicated for use by women for this specific purpose, though the active ingredient has other approved uses for both sexes.


Q: What if Novigra doesn't seem to be working for me after a few weeks?

A: Official guidance confirms that dose modification, when indicated, is a possibility based on an individual’s response and tolerability to the medicine. The official guidance does not provide a standard time frame but acknowledges that individual response can vary.


Q: Does Novigra affect fertility?

A: Regulatory documents include information on fertility. Animal studies conducted on the compound have not shown evidence of impaired fertility. Human data available are generally insufficient to fully characterize a drug-related risk to fertility.


Q: What are the signs of an overdose with Novigra?

A: In clinical studies where the compound was studied at higher doses, the resulting adverse effects were similar to the common side effects (such as headache, flushing, and dizziness). However, these effects generally occurred more frequently and with increased severity at high doses.


Q: Are the side effects of Novigra permanent?

A: Most common adverse reactions, such as headache and flushing, are typically described in official safety reports as transient and mild to moderate in nature. Rare, serious reactions like priapism (a prolonged erection lasting over four hours) or sudden vision loss require immediate medical attention and can result in lasting effects if not treated quickly.

How should Novigra be stored and disposed of?

Novigra (sildenafil citrate) must be stored and disposed of according to strict official guidelines to maintain product integrity and ensure safety.

Storage Requirements

Novigra tablets must be stored at controlled room temperature, specifically between 68 F and 77 F (20 C and 25 C). The medicine must be kept in its original container, which should be tightly closed to protect the contents from both light and moisture. It is a mandatory requirement to keep the product out of the sight and reach of children.

Disposal Instructions

Disposal of unused or expired tablets should be done through an authorized drug take-back program. If a take-back option is unavailable, the medicine should be mixed with an undesirable substance, sealed in a bag, and placed in the household trash. Novigra must not be flushed down the toilet or poured into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Novigra found in:

A-Z Index: